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Summary
The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) was a randomized double-blind placebo and active comparator (celecoxib)
controlled trial of 1583 persons with symptomatic osteoarthritis (OA) of the knee1. Patients randomized to celecoxib had signiﬁcant improve-
ment in knee pain compared to those randomized to placebo. No statistically signiﬁcant improvement in knee pain compared to placebo was
seen among patients randomized to the dietary supplements, although a subset of patients with moderate-to-severe knee pain at entry who
were assigned to the combination of glucosamine and chondroitin sulfate did seem to experience some improvement. Additionally, patients
taking chondroitin sulfate were noted to have a statistically signiﬁcant improvement in knee joint swelling. An exploratory post hoc analysis of
GAIT patients suggested the effect of chondroitin sulfate on joint swelling occurred more often in patients with milder pain and lower Kellgrene
Lawrence Grade at entry.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Osteoarthritis, Glucosamine, Chondroitin.GAIT was a 24-week, double-blind randomized placebo-
controlled trial comparing glucosamine, chondroitin sulfate,
and the two in combination in treating knee pain in patients
with clinical and radiographic knee osteoarthritis1. GAIT
was funded by the National Institutes of Health with the
Coordinating Center at the University of Utah in Salt Lake
City, the Data Repository in Hines, Illinois and the Phar-
macy Center in Albuquerque, New Mexico. There were 16
participating clinics that were afﬁliated with academic rheu-
matology centers across the United States. GAIT patients
were required to have symptomatic (knee pain 6 months;
WOMAC pain 125e400 mm) and radiographic (Kellgren
and Lawrence Grades 2 or 3) criteria for diagnosis of
knee osteoarthritis. GAIT patients were randomized into
one of ﬁve arms: placebo, glucosamine 500 mg three times
daily, chondroitin sulfate 400 mg three times daily, combina-
tion glucosamine plus chondroitin sulfate in the same dos-
ages or celecoxib 200 mg daily. All patients were allowed
to use acetaminophen up to 4 g daily for rescue analgesia.
Study agents were mandated to be of pharmaceutical grade
by the study sponsor so the study was conducted under an
Investigational New Drug application from the federal Food
& Drug Administration2. In order to ensure a balanced dis-
tribution among predetermined pain subgroups, the ran-
domization was stratiﬁed by both baseline WOMAC pain
score where ‘‘mild’’ pain patients were deﬁned as WOMAC
125e300 mm and ‘‘moderate-to-severe’’ deﬁned as
300e400 mm. The primary outcome measure selected
a priori was the summed WOMAC pain subscales deﬁned
by visual analog scales. Only patients with summed scores
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S22having 20% or greater improvement at 24 weeks compared
to baseline.
Subsequent to the development of GAIT, a predeﬁned
response measure that assesses both absolute and relative
improvement in both WOMAC pain and function domains
was proposed by OMERACT-OARSI3. Due to the fact that
each of the domains of the OMERACT-OARSI response
criteria set had been collected prospectively; OMERACT-
OARSI Response was deﬁned as a secondary outcome
measure.
Over 3000 patients were screened for recruitment to
GAIT and 1583 patients were randomized (Fig. 1). There
were no baseline differences among the randomized treat-
ment groups (Table I). The mean age of the study popula-
tion was 58.6 years; almost two-thirds (64%) were
women. The mean BMI was 31.7 kg/m2. The patients had
had osteoarthritis for a mean of 10 years and 44.7% had
Kellgren and Lawrence grade 3 changes on knee radio-
graphs. Over one-quarter (26.9%) of patients had joint
swelling at entry in the study; the prevalence of joint swell-
ing across the treatment groups was similar and ranged
from 24.9% in the glucosamine group to 28.3% in the chon-
droitin sulfate group.
Table II details baseline disease severity; GAIT patients
had a mean of WOMAC pain score of 236 mm; mean
WOMAC stiffness score of 106 mm and mean WOMAC
function score of 772 mm. The mean Health Assessment
Questionnaire (HAQ) at entry was 0.78. No differences
were seen among the ﬁve treatment groups.
Table III outlines response to the study agents; celecoxib
compared to placebo demonstrated a statistically signiﬁcant
improvement (P¼ 0.008) in the primary outcome measure.
A trend toward improvement was also seen in the glucos-
amine/chondroitin sulfate combination group (P¼ 0.09).
Similarly, statistically signiﬁcant improvement was seen
among OMERACT-OARSI Responders in the celecoxib
Fig. 1. GAIT recruitment and follow-up.
Table II
Baseline disease severity
Outcome All patients WOMAC
125e300
WOMAC
301e400
WOMAC pain 236 206 341
WOMAC stiffness 106 97 138
WOMAC function 772 684 1078
HAQ 0.78 0.72 0.98
Table III
Overall response
Treatment group N 20%
Pain (%)
OMERACT-
OARSI (%)
Placebo 313 60.1 56.9
Glucosamine HCl 317 64.0 60.6
Chondroitin sulfate 318 65.4 63.5
GþCS 317 66.6 65.6
Celecoxib 318 70.1 67.3
GþCS vs placebo P¼ 0.09 P¼ 0.02
Celecoxib vs placebo P¼ 0.008 P¼ 0.007
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vation in the combination group was more striking in the
predeﬁned subgroup with moderate-to-severe WOMAC
pain at entry (Table IV).
Another interesting observation from GAIT was noted in
patients who were found to have joint swelling at entry
into the trial. Joint swelling was determined by the investiga-
tor as present or absent at study initiation and completion.
In patients noted to have joint swelling, the swelling im-
proved signiﬁcantly in patients that received chondroitin sul-
fate compared to patients who received placebo. A post hoc
analysis was undertaken to further assess this observation.
Signiﬁcant statistical interaction existed in both Kellgren and
Lawrence Grade and WOMAC stiffness and function sub-
scales. These ﬁndings suggest that patients with Kellgren
and Lawrence Grade 2 radiographic changes were sub-
stantially more responsive to the potential salutary effects
of chondroitin sulfate than those with Kellgren and Law-
rence Grade 3 changes. Further, improvement was more
likely to occur in the chondroitin sulfate treated patients
with lower WOMAC function and stiffness scores and a nu-
merical trend was seen also in patients with lower WOMAC
pain scores.
Adverse events were captured regardless of their related-
ness to agents. Serious adverse events were seen in less
than 4% of patients; speciﬁcally there were no deaths, nonfatal
myocardial infarctions or GI bleeds. One patient taking cele-
coxibhadacerebrovascularaccidentand twopatientshad tran-
sient ischemic attacks (one taking celecoxib and oneTable I
Patient baseline characteristics
Characteristic All patients
N 1583
Age e yrs 58.6
Female e % 64
BMI e kg/m2 31.7
OA Sx e yrs 10.0
KL 3 e % 44.7
Joint swelling e % 26.9
Table IV
Response of ‘‘moderate-to-severe’’ pain subgroup
Treatment group N 20%
Pain (%)
OMERACT-
OARSI (%)
Placebo 70 54.3 48.6
Glucosamine HCl 70 65.7 65.7
Chondroitin sulfate 70 61.4 58.6
GþCS 72 79.2 75.0
Celecoxib 72 69.4 66.7
GþCS vs placebo P¼ 0.002 P¼ 0.001
Celecoxib vs placebo P¼ 0.06 P¼ 0.03
S24 M. C. Hochberg and D. O. Clegg: Potential effects of chondroitin sulfate on joint swellingglucosamine). Because of the concern for the effects of selec-
tive Cox 2 inhibitors on cardiac function this was speciﬁcally as-
sessed. There was no evidence of an increase in ischemic
cardiac events, although there was a signiﬁcantly elevated inci-
denceof palpitations, atrial ﬁbrillation and increasedbloodpres-
sure. With regard to laboratory investigations, increased blood
glucose levels were observed across all groups.
In conclusion, GAIT patients treated with celecoxib ex-
hibited signiﬁcant improvement in osteoarthritis knee pain.
GAIT was hindered by the high placebo response rate that
was observed (60.1%) which could have limited the ability
to detect clinical response. In the moderate-to-severe pain
group there did appear to be changes; however, the sample
size of that group was relatively small impacting the robust-
ness of those ﬁndings. Chondroitin sulfate treated patients
demonstrated a statistically signiﬁcant improvement in joint
swelling compared to placebo treated GAIT patients.
Further, an exploratory post hoc analysis of those chon-
droitin sulfate treated patients suggested that patients with
relatively earlier disease as indicated by relatively milder
symptoms and baseline Kellgren and Lawrence Grade 2radiographic changes seemed most likely to beneﬁt from
chondroitin sulfate treatment.Conﬂict of interest
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